Bionano Genomics (BNGO) Invested Capital (2017 - 2026)

Bionano Genomics has disclosed Invested Capital across 10 years of filings, most recently posting $37.5 million for Q1 2026.

• Invested Capital for Q1 2026 came in at $37.5 million, down 27.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $37.5 million (down 27.92% YoY), and the FY2025 annual result was $44.4 million, up 13.4% from the prior year.
• Invested Capital came in at $37.5 million for Q1 2026 at Bionano Genomics, down from $44.4 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $315.1 million in Q1 2022 to a low of $37.5 million in Q1 2026.
• The 5-year median for Invested Capital is $86.6 million (2024), against an average of $136.4 million.
• Across the five-year window, Invested Capital slumped 63.2% in 2024 and increased 13.4% in 2025, its largest moves.
• Bionano Genomics' Invested Capital stood at $253.3 million in 2022, then plunged by 60.52% to $100.0 million in 2023, then slumped by 60.83% to $39.2 million in 2024, then climbed by 13.4% to $44.4 million in 2025, then slipped by 15.67% to $37.5 million in 2026.
• The last three Invested Capital figures came in at $37.5 million (Q1 2026), $44.4 million (Q4 2025), and $53.5 million (Q3 2025), per Business Quant data.